The Russian government is considering investing in the domestic production of vaccines, by building a new and modernization of the already existing factories, as well as creating conditions for the improvement of quality of their production.
This is expected to be part of the state strategy of drug supply in Russia until 2025, which was recently approved by the Russian government.
It is planned that the majority of funds will be invested in the modernization of the state-owned vaccines enterprises, and in particular Microgen, Russia’s monopoly in the production of certain types of vaccines. The total amount of investment which is expected to be allocated for the project is not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze